Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted) (2020 - 2022)
Historic EPS (Weighted Average and Diluted) for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$0.41.
- Atea Pharmaceuticals' EPS (Weighted Average and Diluted) fell 13106.06% to -$0.41 in Q4 2022 from the same period last year, while for Dec 2022 it was -$1.4, marking a year-over-year decrease of 20447.76%. This contributed to the annual value of -$2.0 for FY2024, which is 2269.94% down from last year.
- Per Atea Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.41 for Q4 2022, which was down 13106.06% from -$0.1 recorded in Q3 2022.
- Atea Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at $2.62 during Q4 2020, with a 5-year trough of -$1.74 in Q3 2020.
- In the last 3 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of -$0.34 in 2021 and averaged -$0.02.
- In the last 5 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 10202.02% in 2021 and then plummeted by 200000.0% in 2022.
- Over the past 3 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at $2.62 in 2020, then plummeted by 49.62% to $1.32 in 2021, then plummeted by 131.06% to -$0.41 in 2022.
- Its EPS (Weighted Average and Diluted) stands at -$0.41 for Q4 2022, versus -$0.1 for Q3 2022 and -$0.38 for Q2 2022.